Targeted drugs represented by epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have brought revolutionary progress in the treatment of advanced NSCLC (Mitsudomi et al., 2010; Rosell et al., 2012; Mok et al., 2017; Soria et al., 2018). Here, EGFR is linked to non-small cell lung carcinoma.